Holen Sie sich die Stockscreener-App
167.90
0.07%
-0.12
Schlusskurs vom Vortag:
$168.02
Offen:
$168.7
24-Stunden-Volumen:
1.79M
Relative Volume:
0.99
Marktkapitalisierung:
$28.02B
Einnahmen:
$16.63B
Nettoeinkommen (Verlust:
$1.39B
KGV:
20.81
EPS:
8.0674
Netto-Cashflow:
$2.12B
1W Leistung:
-0.72%
1M Leistung:
-4.17%
6M Leistung:
-25.34%
1J Leistung:
+21.63%
1-Tages-Spanne:
$163.04
$169.57
1-Wochen-Bereich:
$163.04
$175.93
52-Wochen-Spanne:
$134.65
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Firmenname
Iqvia Holdings Inc
Sektor
Branche
Telefon
919-998-2000
Adresse
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
167.90 | 28.04B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-03-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2026-03-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-11-03 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-10-29 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-04-25 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-09-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-13 | Eingeleitet | BTIG Research | Buy |
| 2023-11-02 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-03-17 | Eingeleitet | Truist | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-11-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-24 | Eingeleitet | Guggenheim | Buy |
| 2022-04-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-16 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-07-07 | Eingeleitet | Stephens | Equal-Weight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Hochstufung | CFRA | Sell → Hold |
| 2019-11-14 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-05-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-10-02 | Bestätigt | Robert W. Baird | Outperform |
| 2018-07-25 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Bestätigt | Stifel | Buy |
| 2018-07-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Hochstufung | Goldman | Neutral → Buy |
| 2018-03-07 | Hochstufung | SunTrust | Hold → Buy |
| 2018-01-19 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Iqvia Holdings Inc Aktie (IQV) Neueste Nachrichten
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IQVIA Holdings Inc stock (US46266C1053): data-driven healthcare group in focus after latest earnings - AD HOC NEWS
Are Wall Street Analysts Predicting IQVIA Holdings Stock Will Climb or Sink? - inkl
IQVIA’s SWOT analysis: healthcare stock faces margin pressures - Investing.com
IQVIA: The Market May Be Missing The AI And Data Story (NYSE:IQV) - Seeking Alpha
Research Alert: CFRA Moderates Rating On Shares Of Iqvia Holdings Inc. To Hold From Buy - Moomoo
IQVIA Holdings stock (US46266C1053): latest earnings highlight data strength and AI ambitions - AD HOC NEWS
IQVIA Signals Confidence with $3.2 Billion Share Repurchase War Chest - BriefGlance
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA (IQV) Fell Despite Strong Fundamentals - Insider Monkey
IQVIA Holdings, Inc. (IQV) Stock Analysis: Growth Potential and Analyst Consensus Point to 35% Upside - DirectorsTalk Interviews
Mid-Cap Stocks: IQVIA (IQV) and First Citizens (FCNCA) Sell SignalsNews and Statistics - IndexBox
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
IQVIA Holdings stock (US46266C1053): earnings, data growth and what investors watch now - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
IQVIA Holdings Inc stock (US46266C1053): earnings momentum and AI narrative draw fresh attention - AD HOC NEWS
Catholic Responsible Investments Equity Index Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative? - Yahoo Finance
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
IQVIA Holdings earnings preview: What to expect - MSN
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $245 - Moomoo
IQVIA Holdings stock (US46266C1053): Expands AI-powered biosimilars deal with Kexing Biopharm - AD HOC NEWS
IQVIA Holdings, Inc. Common Stock (NY: IQV - FinancialContent
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com UK
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Nigeria
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Nigeria
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term - Yahoo Finance
IQVIA Holdings | 4: Statement of changes in beneficial ownership of securities-Director GOGGINS COLLEEN A - Moomoo
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
IQVIA (NYSE: IQV) director Colleen Goggins receives 214 Deferred Shares grant - Stock Titan
IQVIA (NYSE: IQV) director Jim Fasano receives 228 deferred share award - Stock Titan
IQVIA (NYSE: IQV) director awarded 185 deferred shares with 1:1 common conversion - Stock Titan
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why is Larry Robbins Bullish on IQVIA Holdings (IQV) Amid Market Volatility - Kavout
IQVIA Holdings Inc. (IQV): Larry Robbins Is Bullish on This Stock - Insider Monkey
Why IQVIA Holdings (IQV) Is Up 12.8% After Q1 Beat and Bigger Buyback Plan – And What's Next - Sahm
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China - GlobeNewswire Inc.
IQVIA Holdings, Inc. (IQV) Stock Analysis: Robust Growth Potential With A 27.92% Upside - DirectorsTalk Interviews
IQVIA Q1 Earnings Call Highlights - sharewise.com
Here's why you should retain IQV stock in your portfolio now - MSN
IQVIA Holdings stock (US46266C1053): Data?driven healthcare analytics in focus for US investors - AD HOC NEWS
IQVIA board authorizes additional $2B in share repurchases - MSN
Finanzdaten der Iqvia Holdings Inc-Aktie (IQV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):